Skip to main content
Springer Nature Link
Log in

The relationship of the active and latent forms of TGF-β1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of this study was to perform an immunohistochemical analysis from 100 megakaryocytes per sample, analyzing positivity and intensity levels of anti-LAP human TGF-β1 (or Latent TGF-β1) and anti-TGF-β1 (or Active TGF-β1) antibodies from 18 essential thrombocythemia (ET) and 38 primary myelofibrosis (PMF) patients (being 19 pre-fibrotic and 19 fibrotic). Six bone marrow donor biopsies were used as controls. Fibrosis in bone marrow biopsies (BMB) was evaluated according to the European Consensus. The average fibrosis grade differed between each group (P = 0.001 or P = 0.003). Latent TGF-β1 values differed significantly between pre-fibrotic (P = 0.018) and fibrotic (P = 0.031) groups when compared with the control group. The high immunoexpression level of Latent TGF-β1 in the megakaryocytes from patients with myelofibrosis, which was not observed in patients with essential thrombocythemia, may be associated with the development of bone marrow fibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–5.

    PubMed  CAS  Google Scholar 

  2. Foucar K. Bone Marrow Pathology. 2nd ed. Chicago: ASCP Press (American Society for Clinical Pathology); 2001.

    Google Scholar 

  3. Spivak JL, Siver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112:231–9.

    Article  PubMed  CAS  Google Scholar 

  4. Thiele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol. 2006;19:413–37.

    Article  PubMed  CAS  Google Scholar 

  5. Thiele J, Kvanicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–32.

    PubMed  Google Scholar 

  6. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythaemia and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.

    Article  PubMed  CAS  Google Scholar 

  7. Kuter D, Bain B, Mufti G, Bagg A, Hasserjian R. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139:351–62.

    Article  PubMed  CAS  Google Scholar 

  8. Sporn MB, Roberts AB. Transforming growth factor-beta: recent progress and new challenges. J Cell Biol. 1992;119(5):1017–21.

    Article  PubMed  CAS  Google Scholar 

  9. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350–8.

    Article  PubMed  CAS  Google Scholar 

  10. Hyytiäinen M, Penttinen C, Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci. 2004;41:233–64.

    Article  PubMed  Google Scholar 

  11. Massam-Wu T, Chiu M, Choudhury R, Chaudhry SS, Valdwin AK, McGovern A, Baldock C, Shuttleworth A, Kielty CM. Assembly of fibrillin microfibrils governs extracellular deposition of Latent TGF β. J Cell Sci. 2010;123:3006–18.

    Article  PubMed  CAS  Google Scholar 

  12. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-β by thrombospondin -1mechanisms and physiology. Cytokine & Growth Factor Rev. 2000;11:59–69.

    Article  CAS  Google Scholar 

  13. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGF beta activation. J Cell Sci. 2003;116(Pt 2):217–24.

    Article  PubMed  CAS  Google Scholar 

  14. de Caestecker M. The transforming growth factor-beta superfamily of receptors. Cytoquine Growth Factor Rev. 2004;15(1):1–11.

    Article  Google Scholar 

  15. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. Recombinant latent transforming growth factor β 1 has a longer plasma half-life in rats than active transforming growth factor β 1, and a different tissue distribution. J Clin Investig. 1990;86:1976–84.

    Article  PubMed  CAS  Google Scholar 

  16. Vaughan JM, Vale WW. α2-Macroglobulin is a binding protein of inhibin and activin. Endocrinology. 1993;132:2038–50.

    Article  PubMed  CAS  Google Scholar 

  17. Thiele J, Hoeppner B, Zankovich R, Fischer R. Histomorphometry of bone marrow biopsies in primary osteomyelofibrosis/sclerosis (agnogenic myeloid metaplasia)—correlations between clinical and morphological features. Virchows Arch A Pathol Anat Histopathol. 1989;415(3):191–202.

    Article  PubMed  CAS  Google Scholar 

  18. Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W, Bruno E, Barosi G, Xu M, Hoffman R. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007;110(3):986–93.

    Article  PubMed  CAS  Google Scholar 

  19. Dong M, Blobe GC. Role of transforming growth factor-β in hematologic malignancies. Blood. 2006;107(12):4589–96.

    Article  PubMed  CAS  Google Scholar 

  20. Bain BJ, Clark DM, Lampert IA, Wilkins BS. Bone marrow pathology. London: Blackwell; 2001.

    Book  Google Scholar 

  21. Gomori G. Silver impregnation of reticulum in paraffin sections. Am J Pathol. 1937;13:993–1001.

    PubMed  CAS  Google Scholar 

  22. Gomori G. The effect of certain factors on the results of silver impregnation for reticulum fibers. Am J Pathol. 1939;15:493–5.

    PubMed  CAS  Google Scholar 

  23. van der Woude CJ, Kleibeuker JH, Tiebosch ATGM, Homan M, Beuving A, Jansen PLM, Moshage HJ. Diffuse and intestinal type gastric carcinomas differ in their expression of apoptosis related proteins. J Clin Pathol. 2003;56:699–702.

    Article  PubMed  Google Scholar 

  24. Ponce CC, Chauffaille MLF, Ihara SSM, Silva MRR. MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis. Leuk Res. 2012;36(1):93–7.

    Article  PubMed  CAS  Google Scholar 

  25. Kuroda H, Matsunaga T, Terui T, et al. Decrease of Smad 4 gene expression in patients with essential thrombocythaemia may cause an escape from suppression of megakaryopoiesis by transforming growth factor—beta 1. Br J Haematol. 2004;124:211–20.

    Article  PubMed  CAS  Google Scholar 

  26. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495–503.

    Article  PubMed  CAS  Google Scholar 

  27. Bock O, Loch G, Schade U, Wasielewski von R, Schlué J, Kreipe H. Aberrant expression of transforming growth factor B-1 (TGFB-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. J Pathol. 2005;205:548–57.

    Article  PubMed  CAS  Google Scholar 

  28. Yoon SY, Tefferi A, Li CY. Cellular distribution of platelet-derived growth factor, transforming growth factor beta, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol. 2000;104(4):151–7.

    Article  PubMed  CAS  Google Scholar 

  29. Taipale J, Saharinen J, Hedman K, Keski-Oja J. Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrilschem. J Histo Cytochem. 1996;44:875–89.

    Article  CAS  Google Scholar 

  30. Dallas SL, Sivakumar P, Jones CJ, Chen Q, Peters DM, Mosher DF, Humphries MJ, Kielty CM. Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J Biol Chem. 2005;280:18871–80.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors are grateful to Antonio Carlos de Sousa for his excellent technical assistance and to Fabio Tadeu Montesano (Universidade Federal de São Paulo) for statistical analyses. This project was supported by CAPES (Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior) and partially supported by the FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo) grant 07-55948-8.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Pathology, Universidade Federal de São Paulo, Vicente de Carvalho Avenue, 65, # 72, São Paulo, Santos, 11045-501, Brazil

    Cesar Cilento Ponce, Silvia Saiuli M. Ihara & Maria Regina R. Silva

  2. Department of Hematology, Universidade Federal de São Paulo, São Paulo, Brazil

    Maria de Lourdes F. Chauffaille

Authors
  1. Cesar Cilento Ponce
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Maria de Lourdes F. Chauffaille
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Silvia Saiuli M. Ihara
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Maria Regina R. Silva
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Cesar Cilento Ponce.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ponce, C.C., de Lourdes F. Chauffaille, M., Ihara, S.S.M. et al. The relationship of the active and latent forms of TGF-β1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis. Med Oncol 29, 2337–2344 (2012). https://doi.org/10.1007/s12032-011-0144-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0144-1

Keywords